$BCTXL

BriaCell Therapeutics (BCTX) reported biomarker study results showing CAML PD-L1 expression linked to survival in metastatic breast cancer patients treated with immunotherapy. The study involved 111 patients and various treatments, including BriaCell's Bria-IMT regimen. BCTX stock rose 5.88% in pre-market trading to $3.61.

BriaCell Therapeutics presented data at ESMO Congress 2026 showing that changes in PD-L1 expression on circulating CAMLs were linked to survival outcomes in metastatic breast cancer patients treated with immunotherapies, including BriaCell's regimen. The analysis included 111 patients from multiple studies, with significant associations found around three months post-treatment. BriaCell is conducting a Phase 3 study of its Bria-IMT combination regimen, aiming for potential marketing approval.

BriaCell Therapeutics (BCTX) develops targeted immunotherapies for cancer, focusing on 'off-the-shelf' cellular treatments. CEO Dr. Williams discussed their pipeline, including Bria-IMT in a Phase 3 trial for metastatic breast cancer and Bria-PROS+ for prostate cancer, which recently received FDA clearance. The company aims to overcome cost and scaling challenges of traditional therapies.

BriaCell Therapeutics (BCTX, BCT) shares surged 25% then retreated after announcing its melanoma vaccine candidate, Bria-MEL+, reached a genetic engineering milestone. The personalized yet off-the-shelf vaccine aims to treat melanoma by leveraging the immune system. The company cited significant unmet medical needs, with 112,000 new US cases and 8,510 deaths expected in 2026. BriaCell is also developing immunotherapies for breast and prostate cancers.

BriaCell Therapeutics (Nasdaq: BCTX, BCTXL; TSX: BCT) said it arranged manufacturing capacity with FUJIFILM Biotechnologies California to support the remainder of its pivotal Phase 3 study and potential future commercialization of Bria-IMT, an allogeneic cell therapy. Bria-IMT is being tested in metastatic breast cancer with an immune checkpoint inhibitor (NCT06072612).

BriaCell Therapeutics (Nasdaq: BCTX, BCTXL; TSX: BCT) said it hired Charles River Associates (CRA) and Kaleio to support commercial strategy, market-access evaluation, and brand planning for Bria-IMT. Bria-IMT is in an ongoing pivotal Phase 3 study for metastatic breast cancer and is not yet approved.

BriaCell Therapeutics reported positive ASCO 2026 data for Bria-IMT in heavily pretreated metastatic breast cancer. Phase 2 results cited by the company showed 55% survival beyond 1 year and 27% beyond 2 years with the Phase 3-selected regimen; TWiST and quality-of-life analyses from the ongoing Phase 3 Bria-ABC study indicated meaningful benefit with no unexpected safety signals.

BriaCell Therapeutics (Nasdaq: BCTX; TSX: BCT) said its independent Data Safety Monitoring Board reviewed safety data from its pivotal Phase 3 Bria-ABC trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer and raised no safety concerns, recommending continuation without modifications. The DSMB issued its sixth consecutive positive recommendation; the study is under FDA Fast Track.

BriaCell Therapeutics Corp., a clinical-stage biotechnology company, announced the closing of a public offering that generated approximately US$30 million in gross proceeds. The offering included 5,366,726 units, each consisting of one common share (or pre-funded warrant) and one warrant, sold at US$5.59 per unit. The net proceeds will be used for working capital, general corporate purposes, and advancing the company's business objectives.

BriaCell has announced the addition of Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University to its Phase 3 metastatic breast cancer study. This expansion significantly grows its network to 79 clinical sites across 23 US states, aiming to accelerate patient enrollment. The company anticipates reporting top-line data as early as H1-2026 for its Bria-IMT treatment.